FibroGen Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FibroGen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View analyst ratings for FibroGen or view top-rated stocks.

Wall Street analysts have given FibroGen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but FibroGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

FibroGen saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 8,050,000 shares, an increase of 15.0% from the December 31st total of 7,000,000 shares. Based on an average trading volume of 753,400 shares, the days-to-cover ratio is presently 10.7 days. Approximately 9.7% of the company's shares are short sold.
View FibroGen's Short Interest.

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for FibroGen.

FibroGen, Inc. (NASDAQ:FGEN) released its quarterly earnings results on Sunday, February, 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.35. The biopharmaceutical company earned $65 million during the quarter, compared to the consensus estimate of $100.82 million. FibroGen had a negative trailing twelve-month return on equity of 48.19% and a negative net margin of 191.78%. The company's revenue was up 712.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.12) EPS.
View FibroGen's earnings history.

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FGEN stock has decreased by 0.8% and is now trading at $35.13.
View which stocks have been most impacted by COVID-19.

8 brokers have issued 12 month price objectives for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they anticipate FibroGen's stock price to reach $53.57 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price.
View analysts' price targets for FibroGen or view top-rated stocks among Wall Street analysts.

Some companies that are related to FibroGen include CureVac (CVAC), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), BioMarin Pharmaceutical (BMRN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Bausch Health Companies (BHC), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Dr. Reddy's Laboratories (RDY), Ultragenyx Pharmaceutical (RARE), Jazz Pharmaceuticals (JAZZ), Zai Lab (ZLAB) and Arrowhead Pharmaceuticals (ARWR).
View all of FGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil Co. (ATH.TO) (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy Inc. (GTE.TO) (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (10.14%), BlackRock Inc. (8.68%), Price T Rowe Associates Inc. MD (3.99%), Janus Henderson Group PLC (3.74%), Bank of New York Mellon Corp (1.96%) and First Trust Advisors LP (1.56%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, First Trust Advisors LP, Price T Rowe Associates Inc. MD, Dimensional Fund Advisors LP, Alliancebernstein L.P., New York State Common Retirement Fund, Rothschild & Co. Asset Management US Inc., and Candriam Luxembourg S.C.A.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen or view top insider-selling stocks.

FGEN stock was bought by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Vantage Consulting Group Inc, BlackRock Inc., Morgan Stanley, Brown Advisory Inc., Intercontinental Wealth Advisors LLC, Philadelphia Trust Co., and Bank of New York Mellon Corp.
View insider buying and selling activity for FibroGen or or view top insider-buying stocks.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FGEN stock can currently be purchased for approximately $35.13.

FibroGen has a market capitalization of $3.20 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

FibroGen employs 531 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen is headquartered at 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]